Newsroom | 67125 results

NUEVA YORK--(BUSINESS WIRE)--Blue Matter tiene el orgullo de anunciar que ha establecido un área de práctica que prestará exclusivamente servicios a los clientes en investigación y desarrollo (I+D) biofarmacéutico. La dirección de esta práctica estará a cargo de Tara Austraat-Churik, una socia que se incorporó a la firma en septiembre de 2025. Tara Austraat-Churik tiene más de 20 años de experiencia en servicios a los clientes del sector de las ciencias de la vida. Se ha especializado en las ár...

NEW YORK--(BUSINESS WIRE)--Blue Matter a le plaisir d'annoncer la création d'un domaine d'expertise dédié aux clients du secteur de la recherche et développement biopharmaceutique. Ce domaine est dirigé par l'associée Tara Austraat-Churik, qui a rejoint le cabinet en septembre 2025. Tara Austraat-Churik accompagne les acteurs des sciences de la vie depuis plus de 20 ans. Ses domaines d'expertise comprennent le développement et la mise en œuvre de stratégies, la conception de modèles opérationne...

NEW YORK--(BUSINESS WIRE)--Blue Matter annuncia la creazione di una nuova area di consulenza dedicata ai clienti del settore R&S biofarmaceutico e diretta da Tara Austraat-Churik, partner unitasi a Blue Matter nel settembre 2025. Tara Austraat-Churik vanta un’esperienza di oltre 20 anni al servizio di clienti nel settore delle scienze della vita. Molteplici le sue aree di competenza – sviluppo e implementazione di strategie, progettazione di modelli operativi e organizzativi, ottimizzazione...

NEW YORK--(BUSINESS WIRE)--Blue Matter hat einen neuen Praxisbereich gegründet, der auf die Bedürfnisse von Kunden aus der biopharmazeutischen Forschung und Entwicklung (FuE) ausgerichtet ist. Geleitet wird der Praxisbereich von Tara Austraat-Churik, einer Partnerin, die seit September 2025 für Blue Matter tätig ist. Tara Austraat-Churik ist bereits seit über 20 Jahren für Life-Science-Kunden tätig. Ihre Schwerpunkte sind Strategieentwicklung und -umsetzung, Betriebsmodell- und Organisationsges...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes. The C...

St. John’s, NL--(BUSINESS WIRE)--The Canadian Union of Public Employees (CUPE) predicts 2026 to be an incredibly difficult year to defend public services in Newfoundland & Labrador, without public pressure on the provincial government. CUPE members in every public sector are reporting attacks to our services through funding cuts, reduction of services, public-private partnerships (P3s), and the increased use of artificial intelligence. “Our government is systematically deconstructing the pu...

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

LONDON & CAIRO--(BUSINESS WIRE)--Alta Semper Secures USD 57.5 Million from EIB Group and IFC for Growth Fund II to Expand Healthcare Access Across Africa...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit o...

PALO ALTO, Calif.--(BUSINESS WIRE)--Period of transformative growth across all major healthcare verticals follows its Series C, which raised $126 million at a $3.5 billion valuation....